Carisma Therapeutics' solid tumour therapy obtains FDA Fast Track status [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Carisma Therapeutics, Inc. (CARM)
Company Research
Source: Yahoo! Finance
An ex vivo gene-modified autologous chimeric antigen receptor-monocyte cellular therapy, CT-0525 is being analysed in a Phase I clinical trial. The open-label trial is designed to assess the safety, tolerability, and manufacturing feasibility of the therapy. Participants enrolled in the trial will include those with locally advanced (unresectable) or metastatic solid tumours that overexpress HER2 and have advanced following treatment with standard therapies approved presently. The trial will also feature two dose escalation cohorts to determine the optimal dose of CT-0525. With the receipt of FDA Fast Track status, CT-0525 is now poised for an accelerated review process. Carisma Therapeutics CMO Eugene Kennedy said: “Receiving Fast Track designation for CT-0525 from the FDA marks a significant milestone for Carisma, highlighting the FDA's recognition of the serious and life-threatening nature of these malignancies and the potential of CT-0525 to meet this critical medical n
Show less
Read more
Impact Snapshot
Event Time:
CARM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CARM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CARM alerts
High impacting Carisma Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CARM
News
- Carisma Therapeutics Announces Changes to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Carisma Therapeutics Announces Changes to its Board of DirectorsPR Newswire
- Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna [Yahoo! Finance]Yahoo! Finance
- Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with ModernaPR Newswire
- Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
CARM
Earnings
- 5/9/24 - Miss
CARM
Sec Filings
- 7/1/24 - Form 8-K
- 6/27/24 - Form 4
- 6/27/24 - Form 4
- CARM's page on the SEC website